14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg AFM24 + 720 mg AFM24
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Apr 7, 2020 → Jun 24, 2024
NCT ID
NCT04259450About 14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg AFM24 + 720 mg AFM24
14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg AFM24 + 720 mg AFM24 is a phase 1/2 stage product being developed by Affimed for Advanced Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT04259450. Target conditions include Advanced Solid Tumor.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04259450 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumor